AmeriCann Expands Joint Venture Partnership with Bask, Inc. at Massachusetts Cannabis Center
Expanded capacity at MCC allows Bask to meet growing demand
from additional retail licenses
BOSTON, MA / ACCESSWIRE / January 19, 2021 / AmeriCann, Inc. (OTCQB:ACAN), a cannabis company that develops state-of-the-art cultivation processing and product manufacturing facilities, announced that on January 19, 2021 the Company entered into an agreement to expand the cultivation capacity of its Joint Venture partner, Bask, Inc. (“Bask”).
AmeriCann’s flagship project, the Massachusetts Cannabis Center
(“MCC”), is located on a 52-acre parcel in Southeastern Massachusetts. The MCC
project is permitted for 987,000 sq. ft. of cannabis cultivation and processing
, which is being developed in
Bask, one of the premier vertically integrated Massachusetts operators, commenced operations in Building 1, the MCC’s first phase, in February of 2020.
Based on the success of the venture in Building 1, AmeriCann and Bask are expanding the scope of their partnership into Building 2, the next phase of the MCC development. AmeriCann’s planned expansion for Bask represents over a 500% infrastructure increase.
“Bask has been an excellent partner on the initial phase of the Massachusetts Cannabis Center”, stated AmeriCann’s Ben Barton. “As AmeriCann expands the MCC to serve the fast-growing Massachusetts market with the development of Building 2, it was a natural progression to increase the scope of our successful partnership with Bask at this new facility.”
On January 14th, 2021 Bask, Inc. was awarded a Final license for an Adult-Use retailer business at its existing Medical Cannabis dispensary in Fairhaven, Massachusetts. With the addition of Bask’s Adult use license in Fairhaven and other retail opportunities, Bask requires an expanded cultivation footprint to accommodate the corresponding increase in demand.
“As Bask continues to expand its cannabis retail operations it’s necessary for us to expand our cultivation capacity to meet the growing demand from patients and consumers,” stated Bask CEO Chapman Dickerson. “The sustainable, custom built greenhouse facilities and technology provided by AmeriCann at the Massachusetts Cannabis Center allows us to produce quality products efficiently and sustainably.”
Plans for the 400,000 sf Building 2 facility will accommodate both Bask and AmeriCann in dedicated cultivation spaces. Additionally, AmeriCann will operate a centralized product manufacturing facility in Building 2 designed to support the entire 1 million square foot MCC campus. AmeriCann was awarded two licenses from the Massachusetts Cannabis Control Commission including one for cannabis cultivation and one for cannabis product manufacturing.
AmeriCann receives a Revenue Participation fee from Bask on all products cultivated and manufactured at the MCC. AmeriCann previously announced record revenue for 2020 which included positive EBITDA, and was driven by the Revenue Participation fee from Building 1.
AmeriCann (OTCQB:ACAN) is a cannabis company that develops cultivation, processing and product manufacturing facilities.
AmeriCann uses greenhouse technology which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25 percent fewer lights, and utility bills are up to 75 percent less than in typical warehouse cultivation facilities. As such, AmeriCann’s Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs.
AmeriCann is also designing GMP Certified cannabis extraction and product manufacturing infrastructure. The Company has secured licenses to produce cannabis infused products including beverages, edibles, topicals and concentrates. AmeriCann, Inc. plans to operate a Marijuana Product Manufacturing business at the Massachusetts Cannabis Center.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement on Form S-1 which may be viewed at www.sec.gov.
@ACANinfo on Twitter
@AmeriCann on Facebook
@AmeriCannInc on Instagram
AmeriCann, Inc on LinkedIn